Trever G Bivona

List of Publications by Year
in descending order

79 papers	11,139 citations	81900 39 h-index	69250 77 g-index
86 all docs	86 docs citations	86 times ranked	18010 citing authors

#	Article	IF	Citations
1	Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell, 2018, 173, 321-337.e10.	28.9	2,111
2	Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nature Genetics, 2012, 44, 852-860.	21.4	1,049
3	Understanding and targeting resistance mechanisms in NSCLC. Nature Reviews Cancer, 2017, 17, 637-658.	28.4	679
4	Ras signalling on the endoplasmic reticulum and the Golgi. Nature Cell Biology, 2002, 4, 343-350.	10.3	582
5	Liquid Biopsy for Advanced Non-Small Cell LungÂCancer (NSCLC): A Statement Paper from theÂIASLC. Journal of Thoracic Oncology, 2018, 13, 1248-1268.	1.1	515
6	The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nature Genetics, 2015, 47, 250-256.	21.4	434
7	Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers. Nature Genetics, 2017, 49, 1693-1704.	21.4	423
8	FAS and NF-Î²B signalling modulate dependence of lung cancers on mutant EGFR. Nature, 2011, 471, 523-526.	27.8	374
9	Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. Cell, 2020, 182, 1232-1251.e22.	28.9	371
10	RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers. Nature Cell Biology, 2018, 20, 1064-1073.	10.3	276
11	Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. Journal of Thoracic Oncology, 2021, 16, 1647-1662.	1.1	274
12	AXL Mediates Resistance to PI3KÎ± Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas. Cancer Cell, 2015, 27, 533-546.	16.8	263
13	RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALKâ€“positive lung cancer. Nature Medicine, 2015, 21, 1038-1047.	30.7	245
14	Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discovery, 2015, 5, 1040-1048.	9.4	226
15	Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nature Medicine, 2019, 25, 111-118.	30.7	196
16	Polytherapy and Targeted Cancer Drug Resistance. Trends in Cancer, 2019, 5, 170-182.	7.4	183
17	NF-Î²B-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer. Cell Reports, 2015, 11, 98-110.	6.4	178
18	Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts. Science, 2021, 371, .	12.6	166

#	Article	IF	Citations
19	A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nature Medicine, 2016, 22, 472-478.	30.7	145
20	Targeting Oncogenic BRAF: Past, Present, and Future. Cancers, 2019, 11, 1197.	3.7	143
21	Current Landscape of Targeted Therapy in Lung Cancer. Clinical Pharmacology and Therapeutics, 2017, 102, 757-764.	4.7	134
22	Inactivation of Capicua drives cancer metastasis. Nature Genetics, 2017, 49, 87-96.	21.4	130
23	Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. Journal of the National Cancer Institute, 2017, 109, .	6.3	128
24	Principles of Resistance to Targeted Cancer Therapy: Lessons from Basic and Translational Cancer Biology. Trends in Molecular Medicine, 2019, 25, 185-197.	6.7	118
25	Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. Nature Communications, 2017, 8, 410.	12.8	117
26	Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution. Cell, 2022, 185, 1905-1923.e25.	28.9	108
27	Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules. Cell, 2021, 184, 2649-2664.e18.	28.9	102
28	Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E748-57.	7.1	90
29	Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment. Current Opinion in Chemical Biology, 2021, 62, 1-12.	6.1	83
30	Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer. Current Oncology Reports, 2019, 21, 21.	4.0	82
31	TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer. Journal of Clinical Investigation, 2018, 128, 2500-2518.	8.2	73
32	Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma. Npj Precision Oncology, 2017, 1, .	5.4	70
33	Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF -mutant lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 13456-13461.	7.1	65
34	Co-occurring Alterations in the RASâ€“MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer. Clinical Cancer Research, 2020, 26, 439-449.	7.0	64
35	Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma. Nature Communications, 2020, 11, 3675.	12.8	63
36	Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins. Cancer Research, 2019, 79, 546-556.	0.9	59

#	Article	IF	Citations
37	Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. Nature Communications, 2017, 8, 823.	12.8	53
38	Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer. Journal of Experimental Medicine, 2019, 216, 419-427.	8.5	46
39	BRAF Mutations Classes I, II, and III in NSCLC Patients Included in the SLLIP Trial: The Need for a New Pre-Clinical Treatment Rationale. Cancers, 2019, 11, 1381.	3.7	44
40	Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. Journal of Thoracic Oncology, 2020, 15, 1611-1623.	1.1	43
41	Evolution of metastasis: new tools and insights. Trends in Cancer, 2022, 8, 98-109.	7.4	40
42	Combined chemicalâ€“genetic approach identifies cytosolic HSP70 dependence in rhabdomyosarcoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9015-9020.	7.1	33
43	A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases. Oncologist, 2017, 22, 768-773.	3.7	33
44	The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors. Molecular and Cellular Oncology, 2016, 3, e1021441.	0.7	29
45	AUY922 Effectively Overcomes MET- and AXL-Mediated Resistance to EGFR-TKI in Lung Cancer Cells. PLoS ONE, 2015, 10, e0119832.	2.5	28
46	Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. Scientific Reports, 2017, 7, 44206.	3.3	28
47	An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. Cancer Letters, 2016, 380, 144-152.	7.2	26
48	Dampening oncogenic RAS signaling. Science, 2019, 363, 1280-1281.	12.6	25
49	BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. JCO Precision Oncology, 2018, 2, 1-15.	3.0	24
50	Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis. Oncogenesis, 2020, 9, 102.	4.9	24
51	Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFÎ²2-bioenergetics-mitochondrial priming. Oncotarget, 2016, 7, 82013-82027.	1.8	23
52	Recent advances in personalized lung cancer medicine. Personalized Medicine, 2014, 11, 309-321.	1.5	22
53	Emerging application of genomics-guided therapeutics in personalized lung cancer treatment. Annals of Translational Medicine, 2018, 6, 160-160.	1.7	22
54	RAS signaling in ALK fusion lung cancer. Small GTPases, 2016, 7, 32-33.	1.6	20

#	Article	IF	Citations
55	Plasma mRNA expression levels of BRCA1 and TS as potential predictive biomarkers for chemotherapy in gastric cancer. Journal of Translational Medicine, 2014, 12, 355.	4.4	18
56	AXL receptor tyrosine kinase as a therapeutic target in NSCLC. Lung Cancer: Targets and Therapy, 2015, 6, 27.	2.7	18
57	Long non-coding RNA ESCCAL-1 promotes esophageal squamous cell carcinoma by down regulating the negative regulator of APOBEC3G. Cancer Letters, 2020, 493, 217-227.	7.2	17
58	Neoadjuvant Oncogene-Targeted Therapy in Early Stage Nonâ€“Small-Cell Lung Cancer as a Strategy to Improve Clinical Outcome and Identify Early Mechanisms of Resistance. Clinical Lung Cancer, 2016, 17, 466-469.	2.6	16
59	Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer. Journal of Clinical Investigation, 2022, 132, .	8.2	15
60	Tracking Down Response and Resistance to TRK Inhibitors. Cancer Discovery, 2016, 6, 14-16.	9.4	14
61	Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells. Science Translational Medicine, 2022, 14, eabc7480.	12.4	14
62	Engineering Multidimensional Evolutionary Forces to Combat Cancer. Cancer Discovery, 2019, 9, 587-604.	9.4	13
63	Acquired Resistance in Lung Cancer. Annual Review of Cancer Biology, 2020, 4, 279-297.	4.5	13
64	RAS-MAPK in ALK targeted therapy resistance. Cell Cycle, 2015, 14, 3661-3662.	2.6	12
65	Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers. Cell Reports, 2019, 28, 2317-2330.e8.	6.4	12
66	Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer. Cancer Research, 2017, 77, 1200-1211.	0.9	11
67	Exocyst protein subnetworks integrate Hippo and mTOR signaling to promote virus detection and cancer. Cell Reports, 2021, 36, 109491.	6.4	11
68	The evolving understanding of immunoediting and the clinical impact of immune escape. Journal of Thoracic Disease, 2018, 10, 1248-1252.	1.4	10
69	Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation. Clinical Lung Cancer, 2019, 20, e137-e141.	2.6	8
70	Targeting AXL in NSCLC. Lung Cancer: Targets and Therapy, 2021, Volume 12, 67-79.	2.7	8
71	RAS-MAPK signaling influences the efficacy of ALK-targeting agents in lung cancer. Molecular and Cellular Oncology, 2016, 3, e1091061.	0.7	7
72	Inhibition of SHP2 as an approach to block RAS-driven cancers. Advances in Cancer Research, 2022, 153, 205-236.	5.0	7

#	Article	IF	Citations
73	CD74 - ROS1 Fusion in NSCLCÂDetected by Hybrid Captureâ€“Based Tissue Genomic Profiling and ctDNA Assays. Journal of Thoracic Oncology, 2017, 12, e19-e20.	1.1	6
74	Immunohistochemistry to Study YAP in Human Tissue Samples. Methods in Molecular Biology, 2019, 1893, 89-95.	0.9	6
75	Stepwise evolution of therapy resistance in AML. Cancer Cell, 2021, 39, 904-906.	16.8	3
76	Circulating tumor DNA analysis in patients with EGFR mutant lung cancer. Journal of Thoracic Disease, 2018, 10, S4061-S4064.	1.4	2
77	EGFR targeted therapy resistance: current status, challenges, and future outlook. Journal of Thoracic Disease, 2020, 12, 2849-2850.	1.4	2
78	Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids. Journal of Visualized Experiments, 2021, , .	0.3	2
79	Dividing and conquering the variation among variants in EML4-ALK lung cancer. Translational Cancer Research, 2017, 6, S369-S370.	1.0	0